WHO CAN ACCESS GLIVEC?
• Initial treatment (for up to 18 months) of adult patients in the chronic phase of chronic myeloid leukemia expressing the Philadelphia chromosome or the transcript bcr-abl tyrosine kinase, where: (i) treatment with Glivec was commenced prior to 1 September 2002; or (ii) prior treatment with interferon-alfa has failed. Evidence of failure of prior treatment with interferon-alfa is specified in the section 100 restriction (attached) of the Schedule of Pharmaceutical Benefits. The address of the Schedule is http://www1.health.gov.au/pbs/index.htm. • Continuing treatment of adult patients who have received initial treatment with Glivec as a pharmaceutical benefit for the chronic phase of chronic myeloid leukemia and have demonstrated a major cytogenetic response in the preceding 12 months. Major cytogenetic response is defined in the section 100 restriction (attached) of the Schedule of Pharmaceutical Benefits. The address of the Schedule is http://www1.health.gov.au/pbs/index.htm. • Tre
